Evaluation of New Antimalarials. Development of New Antimalarial Drugs.

摘要

During the last nine years, CDRI, Lucknow, has been working in close collaboration with WRAIR, Washington and AFRIMS, Bangkok for standardization of experimental models for screening of new blood schizontocidal, radical curative (anti-relapse) and causal prophylactic agents and the preclinical efficacy trials of the compounds synthesized and developed by US Army antimalarial drug development program and the CDRI. This joint biomedical collaborative research program has led to the establishment of reliable anti-malarial screening models. The reproducibility of the following antimalarial screens at CDRI has been validated using standard drugs and it is encouraging to point out that our results with the standard drugs are in close agreement with the data obtained at AFRIMS, Bangkok and WRAIR, Washington.